New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer’s and Huntington’s disease. Their goal was to find molecular patterns specific to these diseases.
The algorithm was able to detect how these patients’ genes expressed themselves in unique ways over decades. This offers the first long-term view of molecular changes underlying neurodegeneration, an important accomplishment because neurodegenerative diseases develop over years.
Previous studies of neurodegeneration often used static or “snapshot” data, and are therefore limited in how much they can reveal about the typically slow progression of disease. This study aimed to uncover the chronological information contained in large-scale data by covering decades of disease progression, revealing how changes in gene expression over that time are related to changes in the patient’s condition.
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations in both the brain and peripheral body.
“This test could one day be used by doctors to evaluate patients and prescribe therapies tailored to their needs,” says Yasser Iturria-Medina, the study’s first author. “It could also be used in clinical trials to categorize patients and better determine how experimental drugs impact their predicted disease progression.”
Iturria-Medina says his next steps will be testing these models in other diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
AI-analyzed blood test
- AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapy
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer ...
- How AI Revolutionizes Lab Tests: Faster, Smarter, More Personalized
AI revolutionizes lab diagnostics with faster, more precise, and personalized testing, significantly improving patient care and ...
- AI tool may help detect cancer in a few minutes with a drop of blood
An AI-powered tool may be able to detect pancreatic, gastric, or colorectal cancer with a sensitivity of 82–100% and takes just a few minutes, a new study indicates.
- AI-powered test detects cancer from a single drop of blood within minutes
(Web Desk) - Scientists in China have pioneered a revolutionary AI-powered test capable of detecting three major types of cancer using just a single spot of dried blood. Their findings, detailed in a ...
- AI Test Anticipates Knee Osteoarthritis Years in Advance, Offering Hope for Early Intervention
Instead of waiting for signs, doctors can now use a simple blood test, a major medical breakthrough that could help people get treatment sooner.
Go deeper with Google Headlines on:
AI-analyzed blood test
[google_news title=”” keyword=”AI-analyzed blood test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Neurodegenerative disease
- Annovis Bio Inc.: Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases ...
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning ...
- Advances in MRI may open window for treating neurodegenerative diseases
Technology behind MRI machines, among the most complex devices in modern medicine, is still developing after 70 years ...
- Diabetes in youth may increase risk for neurodegenerative disease, like Alzheimer's disease, later in life
Young people with diabetes may have a significantly higher risk of developing Alzheimer's disease later in life, according to a new study by researchers in the Lifecourse Epidemiology of Adiposity and ...
- Crick teams up with Broken String to research insidious neurodegenerative disease
Cambridge genomics company Broken String Biosciences has teamed up with the Francis Crick Institute for a key project targeting a progressive and debilitating neurodegenerative disease.
Go deeper with Google Headlines on:
Neurodegenerative disease
[google_news title=”” keyword=”neurodegenerative disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
